Sunday, 26 June 2022


Astellas to present new roxadustat data in anemia of CKD at ASN kidney week

19 October 2020 | News

42 roxadustat abstracts will be presented at the American Society of Nephrology Kidney Week 2020 Reimagined congress

Image source: Shutterstock

Image source: Shutterstock

Japan-based Astellas Pharma Inc. (Astellas) has announced that in collaboration with FibroGen and AstraZeneca, 42 roxadustat abstracts will be presented at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined congress being held from Oct 22- 25.

Six abstracts (one oral presentation and five ePosters) sponsored by Astellas focus on the use of roxadustat as a treatment in adult patients with anemia of chronic kidney disease (CKD). These abstracts include presentations of the Phase 3 DOLOMITES study and a Japanese Phase 3 CL-0310 study, with both studies evaluating roxadustat versus darbepoetin alfa as a treatment for patients with anemia of CKD, not on dialysis. Other presentations include safety data from two Japanese Phase 3 studies assessing the ophthalmological effects of roxadustat treatment in patients with anemia of CKD on dialysis and not on dialysis, and a study of patients' treatment preferences for anemia of CKD.

FibroGen and AstraZeneca will present roxadustat data (nine oral presentations, including two late-breaking presentations, and 27 ePosters) predominantly focused on the efficacy and safety data from pooled analyses from several Phase 3 clinical studies of patients on dialysis and not on dialysis. Astellas key presentations and ePosters will be available online starting Thursday, October 22, at 10:00 am.

Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in JapanEurope, the Commonwealth of Independent States, the Middle East and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat in the US, China, other markets in the Americas, Australia/New Zealand and Southeast Asia. Roxadustat is under regulatory review in Japan for the treatment of anemia in adult patients with CKD not on dialysis, and in the US and EU in both patients on dialysis and not on dialysis.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account